Maravai LifeSciences Holdings, Inc. MRVI TriLink — Adjusted EBITDA for reportable segments

Similar metrics at other companies

TKREngineered Bearings — Adjusted EBITDA for reportable segments

$159M-0.1%

TKRIndustrial Motion — Adjusted EBITDA for reportable segments

$91.3M+36.1%

LUMNReportable Segment — Adjusted EBITDA

$1.28B+54.1%

OTEXReportable Segment — Adjusted EBITDA

$506.65M+14.1%

CRONReportable Segment — Adjusted EBITDA

$13.09M+675%

LAMRReportable Segment — Adjusted EBITDA

$303.51M+9.0%

FAQ

What is Maravai LifeSciences Holdings, Inc.'s trilink — adjusted EBITDA for reportable segments?

Maravai LifeSciences Holdings, Inc. (MRVI) reported trilink — adjusted EBITDA for reportable segments of $7.03M in Q2 2026.

How has Maravai LifeSciences Holdings, Inc.'s trilink — adjusted EBITDA for reportable segments changed year-over-year?

Maravai LifeSciences Holdings, Inc.'s trilink — adjusted EBITDA for reportable segments increased by 196.7% year-over-year, from -$7.27M to $7.03M.

What does trilink — adjusted EBITDA for reportable segments mean?

Measures the operational profitability of the TriLink segment by excluding interest, taxes, depreciation, amortization, and non-recurring charges. This metric serves as a key indicator of the segment's core cash-generating capability and operational efficiency. It allows investors to assess the underlying performance of the nucleic acid production business independent of capital structure or accounting adjustments.